Merck to Buy Cidara in $9.2 Billion Deal as Sales Drop Looms

Merck & Co. agreed to acquire Cidara Therapeutics Inc., a biotech company developing a flu treatment, as part of its ongoing efforts to make up for the upcoming patent loss of its blockbuster cancer drug Keytruda.